First published 10/1/2026, 8:02:15 AM · Last updated 10/1/2026, 8:02:15 AM

European Association of Nuclear Medicine (EANM) Focus Meeting 7: Consensus on the role of molecular imaging and fluid biomarkers in diagnosis, treatment eligibility, and monitoring in Alzheimer’s Disease

A journal article reports a consensus from EANM Focus Meeting 7 on the role of molecular imaging and fluid biomarkers in diagnosis, treatment eligibility, and monitoring of Alzheimer’s disease. The source is a published journal article by Elsevier BV dated 2026-09-01.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 6/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The consensus addresses diagnostic, treatment-eligibility, and monitoring approaches for Alzheimer’s disease.

Sources

European Association of Nuclear Medicine (EANM) Focus Meeting 7: Consensus on the role of molecular imaging and fluid biomarkers in diagnosis, treatment eligibility, and monitoring in Alzheimer’s Disease

Report an issue